TALEN-mediated inactivation of Klk5 and Klk7 rescues lethal phenotype of Netherton syndrome mouse model
TRANSGENIC RESEARCH
Authors: Kasparek, Petr; Ileninova, Zuzana; Benada, Oldrich; Zbodakova, Olga; Kanchev, Ivan; Sedlacek, Radislav
Abstract
Evaluation of Kallikrein-related Peptidase 5 Expression and its Significance for Breast Cancer Patients: Association with Kallikrein-related Peptidase 7 Expression
ANTICANCER RESEARCH
Authors: Talieri, Maroulio; Devetzi, Marina; Scorilas, Andreas; Prezas, Panagiotis; Ardavanis, Alexandros; Apostolaki, Aikaterini; Karameris, Andreas
Abstract
Background: Kallikrein-related peptidases (KLKs) have been proposed as potential cancer biomarkers. Contradictions in literature led us to clarify the role of KLK5 as a breast cancer predictor, as well as its association with KLK7 expression. Patients and Methods: Semi-quantitative RT-PCR detected KLKs 5 and 7 in 80 breast tissues, 74 neoplastic and 6 normal. Steroid hormone receptors were quantified in all samples. Associations between KLK5 status and clinicopathological variables, as well as disease-free survival (DFS) and overall survival (OS) of patients were analyzed. Results: Forty tumor tissues showed high KLK5 expression, which was significantly associated with estrogen receptor status. Significant co-expression of KLKs 5 and 7 was observed in the same cancer samples (p=0.02). Increased KLK5 expression was a statistically significant independent prognostic factor for DFS (p=0.009 univariate analysis and p=0.028 multivariate analysis) and OS of patients (p=0.014, univariate analysis). Conclusion: Increased KLK5 expression can contribute to the prognosis of DFS and OS of breast cancer patients. KLKs 5 and 7 are co-expressed in breast cancer.
COA
Publication 
Loading ......
